Nymox Pharmaceutical Corporation’s (NASDAQ:NYMX) shares were up 35.2% after the company announced positive results from the seven-year, prospective, placebo-controlled, double-blind study on its lead candidate, fexapotide (NX-1207).
The study evaluated fexapotide, in comparison to placebo, in men (n=995) with prostate enlargement (benign prostate hyperplasia/BPH) symptoms. Subjects were evaluated thoroughly to exclude any prostate cancer prior to treatment with fexapotide. They were followed for up to seven years (median of five years) after treatment.
Data from the study demonstrated that men receiving fexapotide revealed a major reduction in the incidence of prostate cancer, compared to placebo, as well as to the known and expected normal incidence of the disease. Data also revealed a statistically significant and very low incidence of 1.3% for prostate cancer.
We note that Nymox is developing fexapotide in a phase III study for the treatment of BPH and in a phase II study for the treatment of low-grade localized prostate cancer.
We remind investors that earlier this year, the company has announced results from a phase II study – NX03-0040 – on fexapotide for the treatment of localized prostate cancer. The study met its pre-determined endpoints. There was a significant improvement in cancer progression outcomes in the fexapotide-treated patient groups.
Stocks to Consider:
Investors interested in the health care sector may consider stocks such as Pfizer Inc. (NYSE:PFE) , ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) and Retrophin, Inc. (NASDAQ:RTRX) . All these stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
PFIZER INC (PFE): Free Stock Analysis Report
RETROPHIN INC (RTRX): Free Stock Analysis Report
ANI PHARMACEUT (ANIP): Free Stock Analysis Report
Original post
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Nymox (NYMX) Stock Up On Positive 7-Year Fexapotide Data
Published 06/23/2016, 08:51 AM
Updated 07/09/2023, 06:31 AM
Nymox (NYMX) Stock Up On Positive 7-Year Fexapotide Data
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or
remove ads
.
Latest comments
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.